Adrenal insufficiency and the use of mineralocorticoid treatment in male patients with adrenoleukodystrophy; a retrospective analysis of an institutional database.

Autor: Zekarias KL; Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, 420 Delaware St SE, MMC 101, Minneapolis, MN, 55455, USA. kzekaria@umn.edu., Salim M; Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, 420 Delaware St SE, MMC 101, Minneapolis, MN, 55455, USA., Tessier KM; Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, USA., Radulescu A; Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, 420 Delaware St SE, MMC 101, Minneapolis, MN, 55455, USA.
Jazyk: angličtina
Zdroj: BMC endocrine disorders [BMC Endocr Disord] 2024 Sep 09; Vol. 24 (1), pp. 181. Date of Electronic Publication: 2024 Sep 09.
DOI: 10.1186/s12902-024-01712-3
Abstrakt: Introduction: Adrenoleukodystrophy (ALD) patients exhibit three primary clinical phenotypes: primary adrenal insufficiency, adrenomyeloneuropathy, and cerebral demyelination due to the accumulation of saturated very long-chain fatty acids in the adrenal cortex and central nervous system white matter and axons. We investigated the diagnosis of adrenal insufficiency (AI) and the use of mineralocorticoid treatment in male ALD patients.
Methods: A retrospective chart review of electronic medical records was conducted for all ALD patients at a single institution between January 1, 2011, and December 6, 2021.
Results: Among the 437 ALD patients, 82% were male and 18% were female. Of the male ALD patients, 60% (213 out of 358) had a diagnosis of AI, and 39% (84 out of 213) of those with AI were prescribed mineralocorticoid replacement therapy.
Conclusion: AI is highly prevalent among ALD patients, with approximately 40% of those with a diagnosis of AI undergoing mineralocorticoid replacement therapy. Further research is warranted to delineate the characteristics of patients predisposed to developing mineralocorticoid deficiency within the context of ALD and AI.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje